Carregant...

Effect of Once-Weekly Dulaglutide on Glucose Levels in Japanese Patients with Type 2 Diabetes: Findings from a Phase 4, Randomized Controlled Trial

INTRODUCTION: Dulaglutide is a recombinant glucagon-like peptide-1 immunoglobulin G4 Fc fusion protein approved for treating patients with type 2 diabetes (T2D). The aim of this study was to assess postprandial data over 4 weeks for dulaglutide (0.75 mg) versus placebo after a standardized test meal...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Diabetes Ther
Autors principals: Inoue, Megumi, Shiramoto, Masanari, Oura, Tomonori, Nasu, Risa, Nakano, Masako, Takeuchi, Masakazu
Format: Artigo
Idioma:Inglês
Publicat: Springer Healthcare 2019
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6531535/
https://ncbi.nlm.nih.gov/pubmed/30949907
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-019-0605-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!